50 States Settle With Pfizer

NEW YORK - Pfizer Inc. said May 13 it would set aside $430 million dollars to settle federal and state claims that its Warner-Lambert subsidiary engaged in extensive marketing of the epilepsy drug Neurontin for 'off-label' uses despite little research into efficacy or safety.

Attorneys general from all 50 states participated in the settlement and will share $38 million. Pfizer also agreed to settle claims by the National Association of Medicaid Fraud Units.

Pfizer said in a statement that the settlement ended all outstanding investigations by federal and state authorities into marketing of Neurontin (gabapentin) by Warner-Lambert's Parke-Davis Division. Those …